The Pfizer vaccine is mainly reaching the world’s rich. Selling mainly to rich countries, by April, Pfizer had earned around US$900 million in pre-tax profits from vaccine sales. Not a single major vaccine or pharmaceutical company has joined the WHO Covid-19 Technology Access Pool (C-TAP) initiative to share such knowledge. Taxpayer-funded basic and applied research has been essential for Covid-19 vaccine development. As governments have paid, directly and indirectly, for vaccine development, they can now quickly accelerate further progress needed.

Source: The Edge Markets May 29, 2021 04:07 UTC